10q10k10q10k.net
AIM ImmunoTech Inc.

AIM ImmunoTech Inc.AIMEarnings & Financial Report

NYSE

AIM ImmunoTech Inc., formerly known as Hemispherx Biopharma Inc., is a biopharmaceutical company based in Ocala, Florida that is focused on the research and development of therapeutics to treat multiple types of cancers, various viruses and immune-deficiency disorders. Founded in 1990, the company has twenty-three employees.

NextMar 31, 2026

AIM Q3 2025 Key Financial Metrics

Revenue

$26.0K

Gross Profit

N/A

Operating Profit

$-2.4M

Net Profit

$-3.3M

Gross Margin

N/A

Operating Margin

-9411.5%

Net Margin

-12630.8%

YoY Growth

-25.7%

EPS

$1.57

Financial Flow

AIM ImmunoTech Inc. Q3 2025 Financial Summary

AIM ImmunoTech Inc. reported revenue of $26.0K for Q3 2025, with a net profit of $-3.3M (-12630.8% margin). Cost of goods sold was N/A, operating expenses totaled N/A.

Key Financial Metrics

Total Revenue$26.0K
Net Profit$-3.3M
Gross MarginN/A
Operating Margin-9411.5%
Report PeriodQ3 2025

AIM ImmunoTech Inc. Annual Revenue by Year

AIM ImmunoTech Inc. annual revenue history includes year-by-year totals (for example, 2024 revenue was $170.0K).

YearAnnual Revenue
2024$170.0K
2023$202.0K
2022$141.0K

Income Statement

Q4 2023Q1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025
Revenue$65000$40000$50000$35000$45000$16000$25000$26000
YoY Growth14.0%-18.4%19.0%-23.9%-30.8%-60.0%-50.0%-25.7%

Balance Sheet

Q4 2023Q1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025
Assets$19.4M$16.2M$15.7M$13.6M$8.6M$6.2M$4.1M$5.5M
Liabilities$9.1M$11.4M$9.6M$10.7M$9.9M$10.1M$10.7M$11.6M
Equity$10.2M$4.8M$6.1M$2.9M$-1.3M$-3.9M$-6.5M$-6.1M

Cash Flow

Q4 2023Q1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025
Operating CF$-9.8M$-4.8M$-3.0M$-3.1M$-4.0M$-2.4M$-1.5M$-5.1M